Identification of potential therapeutic targets for papillary thyroid carcinoma by bioinformatics analysis

Ming Zhao1, Ke-Jing Wang1, Zhuo Tan1

  • 1Department of Head and Neck Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China.

Oncology Letters
|February 13, 2016
PubMed

Insights

This study identified key genes like S100A6, MET, and CDKN1C as potential therapeutic targets for papillary thyroid carcinoma (PTC). These findings offer new insights into PTC mechanisms and treatment strategies.

Area of Science:

  • Oncology
  • Genomics
  • Bioinformatics

Background:

  • Papillary thyroid carcinoma (PTC) is a common endocrine malignancy.
  • Understanding the molecular mechanisms of PTC is crucial for developing effective therapies.

Purpose of the Study:

  • To identify novel therapeutic targets for PTC.
  • To elucidate the underlying molecular mechanisms of PTC development.

Main Methods:

  • Downloaded and analyzed gene expression profile (GSE53157) from the Gene Expression Omnibus database.
  • Identified differentially-expressed genes (DEGs) between PTC and normal thyroid tissues.
  • Performed Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses.
  • Constructed protein-protein interaction (PPI) and microRNA (miRNA) regulatory networks.
  • Integrated PPI and miRNA networks to identify key target genes.

Main Results:

  • Identified 668 DEGs between PTC and normal tissues.
  • Selected key target genes including S100 calcium binding protein A6 (S100A6), met proto-oncogene (MET), and cyclin-dependent kinase inhibitor 1C (CDKN1C).
  • S100A6, MET, and CDKN1C were implicated in PTC progression and development.

Conclusions:

  • S100A6, MET, and CDKN1C represent potential specific therapeutic targets for PTC.
  • Further experimental validation is necessary to confirm these findings and their therapeutic utility.